See more : Castelnau Group Limited (CGL.L) Income Statement Analysis – Financial Results
Complete financial analysis of Talaris Therapeutics, Inc. (TALS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Talaris Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tesserent Limited (TNT.AX) Income Statement Analysis – Financial Results
- Jolimark Holdings Limited (JLMKF) Income Statement Analysis – Financial Results
- Spexis AG (PPHOF) Income Statement Analysis – Financial Results
- Equillium, Inc. (EQ) Income Statement Analysis – Financial Results
- X-FAB Silicon Foundries SE (0ROZ.L) Income Statement Analysis – Financial Results
Talaris Therapeutics, Inc. (TALS)
About Talaris Therapeutics, Inc.
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 57.01M | 34.25M | 15.28M | 13.37M |
| General & Administrative | 19.47M | 13.26M | 7.41M | 5.01M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.47M | 13.26M | 7.41M | 5.01M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 76.48M | 47.51M | 22.68M | 18.38M |
| Cost & Expenses | 76.48M | 47.51M | 22.68M | 18.38M |
| Interest Income | 900.00 | 0.00 | 400.00 | 200.00 |
| Interest Expense | 2.58M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.16M | 623.00K | 447.00K | 379.00K |
| EBITDA | -74.32M | -46.88M | -22.24M | -18.00M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -76.48M | -47.51M | -22.68M | -18.38M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.58M | -326.00K | -23.00K | 223.00K |
| Income Before Tax | -73.89M | -47.83M | -22.71M | -18.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.17M | 326.00K | 23.00K | -223.00K |
| Net Income | -68.73M | -48.16M | -22.73M | -17.93M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -16.66 | -16.53 | -34.00 | -28.09 |
| EPS Diluted | -16.66 | -16.53 | -34.00 | -28.09 |
| Weighted Avg Shares Out | 4.12M | 2.91M | 668.51K | 638.33K |
| Weighted Avg Shares Out (Dil) | 4.12M | 2.91M | 668.51K | 638.33K |
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics
TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS
3 Hot Penny Stocks to Watch Before Next Week
„MIR M: Vanguard & Vagabond“ – neues MMORPG von Wemade startet weltweit
Novel Spectrometry Platforms Market, 2022-2035: Need for Automation, Reproducibility and Higher Sensitivity Drives Adoption - ResearchAndMarkets.com
Talaris (TALS) Down on Patient Death From Renal Transplant Study
Talaris Therapeutics' stock falls 21% after reporting patient death in clinical trial
Source: https://incomestatements.info
Category: Stock Reports